Credit Suisse’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Credit Suisse’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-10,800	Closed	-$846K	–	4793
2015 Q1	$846K	Sell	10,800 -10,000	-48%	-$620K	﹤0.01%	3127
2014 Q4	$1.26M	Sell	20,800 -9,200	-31%	-$462K	﹤0.01%	2938
2014 Q3	$1.28M	Buy	+30,000	New	+$1.61M	﹤0.01%	2847
2014 Q2	–	Sell	-27,150	Closed	-$1.76M	–	5019
2014 Q1	$1.76M	Buy	27,150 +9,000	+50%	+$609K	﹤0.01%	2616
2013 Q4	$1.02M	Buy	+18,150	New	+$1.02M	﹤0.01%	3262

Other funds holding OREX

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Credit Suisse's OREX Position: Q2 2018 in Review

Credit Suisse sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2018, closing a stake of 165,770 shares — an estimated $35K sold.

Credit Suisse first reported a position in OREX in Q2 2013 and held it in 19 quarters. The position peaked at $19.9M in Q2 2015. 4 funds tracked by Wall St. Rank hold OREX as of Q2 2018.

Credit Suisse reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
Credit Suisse sold 165,770 Orexigen Therapeutics, Inc. shares in Q2 2018, an estimated $35K.
Credit Suisse first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 19 quarters.
Credit Suisse's Orexigen Therapeutics, Inc. position peaked at $19.9M in Q2 2015.
4 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2018.

Based on Credit Suisse's 13F filing for Q2 2018, filed 14 Aug 2018.